

# The 3rd International Online Conference on Toxins



10-12 September 2025 | Online

Trigonelline, a jellyfish alkaloid, in the restoration of cathepsin B and D activity in the substantia nigra and caudate putamen in a rat model of Parkinson's disease

> Alquiandra S.F. Mançano<sup>1</sup>, Juliana Pina<sup>1</sup>, Ana Carolina P. Campos<sup>2</sup>, Rosana L. Pagano<sup>2</sup>, Bianca Zychar<sup>3</sup>, Juliana Mozer Sciani<sup>1</sup> <sup>1</sup> Laboratory of Natural Products, Universidade São Francisco, Bragança Paulista, CEP: 12916-900, Brasil <sup>2</sup> Laboratory of Neuroscience, Hospital Sírio-Libanês, São Paulo, CEP 01308-050, Brasil

<sup>3</sup> Laboratory of Physiopathology, Instituto Butantan, São Paulo, CEP: 05503-900, Brasil

alquiandra.mancano@mail.usf.edu.br

#### INTRODUCTION


Parkinson's disease (PD) is characterized by the progressive degeneration of dopaminergic neurons in the nigrostriatal pathway, primarily due to misfolded  $\alpha$ -synuclein. Lysosomes play a crucial role in degrading these proteins through cathepsins, a mechanism impaired in PD. Trigonelline (TGN), an alkaloid found in plants and identified in jellyfish by our research group, has been shown to inhibit caspase-1. Its analog, nicotinic acid, has demonstrated beneficial effects in PD models. This study investigates the modulation of cathepsin D (CTSD) and cathepsin B (CTSB) activity by TGN in the substantia nigra (SN) and caudate putamen (CPu) of PDinduced rats.

## METHOD Control (striatal saline injection + oral vehicle) PD (striatal 6-OHDA + oral vehicle) PD + TGN (striatal 6-OHDA + oral TGN treatment) Day 0 Day 19 Day 14 Striatal Treated with after the final injections TGN (50 mg/Kg; treatment, once daily for animals the five consecutive were days) euthanized, and the SN and CPu were collected


For enzymatic activity analysis using specific substrates. Fluorescence was measured every five minutes over 50 minutes.

#### **RESULTS & DISCUSSION**

Preliminary findings indicate that in the PD model, CTSD activity in the right SN was reduced (Control = 1.65 AUF/min; PD = 0.14 AUF/min), as was CTSB activity (Control = 2.37 AUF/min; PD = 1.37 AUF/min). TGN treatment enhanced the activity of both enzymes (CTSD = 0.79 AUF/min; CTSB = 3.07 AUF/min).



In the CPu, CTSD activity remained similar among groups, whereas CTSB activity was reduced in PD but was not restored by TGN



### CONCLUSION

TGN enhances the activity of key lysosomal enzymes in the SN, which is associated with removing protein aggregates. These findings suggest a potential role for TGN in maintaining lysosomal functionality in this critical brain region affected by PD.

#### REFERENCES

Moreno RI, Zambelli VO, Picolo G, Cury Y, Morandini AC, Marques AC, Sciani JM. Caspase-1 and Cathepsin B Inhibitors from Marine Invertebrates, Aiming at a Reduction in Neuroinflammation. Mar Drugs. 2022 Sep 29;20(10):614. doi: 10.3390/md20100614.

Mirzaie, M., Khalili, M., Kiasalari, Z. et al. Neuroprotective and Antiapoptotic Potential of Trigonelline in a Striatal 6-Hydroxydopamine Rat Model of Parkinson's Disease. Neurophysiology 48, 176–183 (2016). https://doi.org/10.1007/s11062-016-9586-6

Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983

Jun;16(2):109–10.

Ford B. Pain in Parkinson's disease. Clin Neurosci. 1998;5(2):63-72. Paxinos GW, Watson C. The Rat Brain: In Stereotaxic Coordinates. 6th ed. San Diego, CA: Academic Press; 2005.